Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
48 results about "Hepatocyte Growth Factor Receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Hepatocyte growth factor receptor (1390 aa, ~156 kDa) is encoded by the human MET gene. This protein is involved in tyrosine phosphorylation and ligand-dependent signaling.
Five-membered heterocycle pyrimidine compounds, preparation method and application thereof
The invention relates to five-membered heterocycle pyrimidine compounds, their pharmaceutical acceptable salt or pharmaceutical acceptable solvate and a preparation method thereof. The five-membered heterocycle pyrimidine compounds possess a c-Met inhibitory activity and have a structure as shown in the general formula 1. The invention also relates to a drug combination which contains the compounds and applications of the compounds in preparation of drugs used for prevention and treatment of in vivo Hepatocyte Growth Factor Receptor (HGFR) related abnormal cell proliferation, morphologic change and hyperkinesis associated diseases, angiogenesis or cancer metastasis associated diseases, and especially for prevention and treatment of tumor growth and metastasis.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ActiveUS20110201038A1Easy to adaptMicrobiological testing/measurementDisease diagnosisInterleukin 10Soluble P-Selectin
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.
Owner:ASTUTE MEDICAL
Novel pyridine derivative and pyrimidine derivative (3)
InactiveCN101198590APrevent proliferationPromote new lifeOrganic active ingredientsOrganic chemistryHydrogen atomHalogen
General formula (I) (wherein, R 1 It is a 3- to 10-membered non-aromatic heterocyclic group or the like. R 2 and R 3 for a hydrogen atom. R 4 , R 5 , R 6 and R 7 Same or different, hydrogen atom, halogen atom, C 1－6 Alkyl etc. R 8 for hydrogen atoms, etc. R 9 It is a 3- to 10-membered non-aromatic heterocyclic group or the like. n is an integer of 1-2. X is a group represented by the formula -CH= or a nitrogen atom. ) or their salts or their hydrates have excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibit antitumor activity, angiogenesis inhibitory activity or cancer metastasis inhibitory activity.
Owner:EISIA R&D MANAGEMENT CO LTD
Pyridine chemical, its preparation method, and pharmaceutical composition containing the chemical and application thereof
The invention relates to a pyridine chemical shown as the following general formula and having c-Met and / or ALK inhibitory activity and its pharmaceutically-acceptable salt or pharmaceutically-acceptable solvate, a preparation method thereof, a pharmaceutical composition containing the chemicals, and applications of the chemicals in preparation of medicines for preventing and treating abnormal proliferation and morphological change of cells and related diseases, such as hyperkiesis, related to hepatocyte growth factor receptor (HGFR) and / or anaplastic lymphoma kinase (ALK) in organism and diseases related to vascularization or cancerometastasis, especially application in preparation of medicines for treating and preventing growth and metastasis of tumor.
Owner:CHIA TAI TIANQING PHARMA GRP CO LTD
Hepatocyte growth factor receptor splice variants and methods of using same
InactiveUS20080159992A1Enhanced inhibitory effectGood treatment effectSenses disorderPeptide/protein ingredientsMET Receptor Tyrosine KinasePolynucleotide
Novel polypeptides that are splice variants of c-Met, the receptor for hepatocyte growth factor and polynucleotides encoding same are provided. Methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention, are also provided.
Owner:COMPUGEN
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ActiveUS8778615B2Easy to adaptMicrobiological testing/measurementAntibody ingredientsInterleukin 10Soluble P-Selectin
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.
Owner:ASTUTE MEDICAL
HGF-SF monoclonal antibody combinations
InactiveUS7459536B1Increase the amount addedImmunoglobulins against growth factorsAntibody ingredientsMonoclonal antibodyCell growth
The present invention provides a combination of anti-HGF / SF antibodies that specifically bind HGF / SF and inhibits HGF / SF activity. The present invention further provides a combination of anti-HGF / SF antibodies comprising three or more anti-HGF / SF antibodies selected from the group consisting of antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B10, antibody #5 produced from hybridoma 13B1-E4-E10, antibody #7 produced from hybridoma 15D7-B2, and antibody #10 produced from hybridoma 31D4-C9-D4. The invention also provides a method of treating cancer in a subject comprising administering to the subject a combination of anti-HGF / SF antibodies whereby the antibodies bind to a hepatocyte growth factor, whereby the binding of the antibodies to a hepatocyte growth factor results in an inhibition of hepatocyte growth factor binding to the hepatocyte growth factor receptor, whereby the inhibition of hepatocyte growth factor binding to receptor causes an inhibition of cancer growth, thereby treating the cancer.
Owner:US DEPT OF HEALTH & HUMAN SERVICES
Monoclonal antibodies against c-met
ActiveUS20130216548A1Highly effectiveHighly specificPeptide/protein ingredientsGenetic material ingredientsMonoclonal antibodyMET Receptor Tyrosine Kinase
Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
Owner:GENMAB AS
Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates
Owner:AGOURON PHARMA INC
High affinity binding site of hgfr and methods for identification of antagonists thereof
InactiveUS20090298079A1High sensitivityLess side effectsPeptide/protein ingredientsGenetic material ingredientsActive agentNucleotide
Use of a polynucleotide encoding or a polypeptide comprising at least the extracellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and / or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
Owner:METHERESIS TRANSLATIONAL RES
Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same
An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X=CH or N; Z=O or S; L=O or S; M=CR10R11, wherein R10 and R11 =H, alkyl, or alkoxy, NR12 wherein R12=H or alkyl; R1, R2, and R3=H or optionally substituted alkoxy; R4=H; R5-R8=H, halogen, alkoxy or the like; and R9=alkyl optionally substituted by -R14, -T-R15, or -NR16R17 wherein T=O, S, or NH; R14 =an optionally substituted carbocyclic or heterocyclic ring; and R15-R17=alkyl or an optionally substituted carbocyclic or heterocyclic ring, or -NR18R19 wherein R18 and R19 =H, optionally substituted alkyl, or an optionally substituted carbocylic or heterocyclic ring, or optionally substituted carbocyclic or heterocyclic ring.
Owner:KIRIN PHARMA
Effects and application of artemisinin and its derivative in inhibition of platelet-derived growth factor receptor A
ActiveCN103251585AInhibition of activationArrest protein stabilityDigestive systemUrinary disorderSignalling pathwaysCell membrane
The invention relates to effects and application of artemisinin and its derivative in inhibition of platelet-derived growth factor receptor A. Particularly, artemisinin and its derivative directly act on a molecular target platelet-derived growth factor receptor A (PDGFR alpha) of a tumor and combines with PDGFR alpha on a cell membrane to inhibit activation of tyrosine kinase at the intracellular domain of PDGFR alpha, inhibit protein stability of PDGFR alpha, and promote a ubiquitin-dependent proteasome mediated degradation process. The artemisinin and its derivative has dose-dependent cell growth inhibition and migration invasion inhibition effects on PDGFR alpha highly expressed tumor cells, and also can inhibit activation of signaling pathways PI3K / AKT and MAPK / ERK.
Owner:SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
Novel triazolopyrazine derivative and use thereof
ActiveCN104703988AInhibitory activityOrganic active ingredientsSenses disorderDiabetic retinopathyKinase activity
The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing the same as an active ingredient for inhibiting c-Met tyrosine kinase activity; and to a pharmaceutical composition for preventing or alleviating a hyper-proliferative disorder. The present invention efficiently inhibits c-Met tyrosine kinase activity, and thus can be useful as a therapeutic agent against various hyper-proliferative disorders associated with excessive cellular proliferation and growth due to abnormal kinase activity, for example, cancer, psoriasis, rheumatoid arthritis, or diabetic retinopathy.
Owner:KOREA RES INST OF CHEM TECH +1
3-amino-benzo five-membered heterocyclic compounds and preparation method and applications thereof
InactiveCN105175351AAchieve separationGood c-Met inhibitory activityOrganic active ingredientsOrganic chemistryDiseaseSolvent
The invention provides 3-amino-benzo five-membered heterocyclic compounds having the structure represented by the general formula (I) and pharmaceutical acceptable salts or pharmaceutical acceptable solvates thereof, and a preparation method and an application thereof in preparation of drugs for inhibiting the activity of tyrosine kinase c-Met, an application thereof in preparation of drugs for prevention or treatment of diseases related to cell abnormal proliferation, morphologic changes and hyperkinesia which are related to hepatocyte growth factor receptor (c-Met) in biological bodies and diseases related to angiogenesis or cancerometastasis, and particularly an application thereof in preparation of drugs for treatment or prevention of tumor growth and metastasis. Active separation of c-Met and VEGFR2 by the target compounds is achieved, and moreover, the better c-Met inhibitory activity is retained.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Medicament composition containing sorafenib, cMet inhibitors and EGFR tyrosine kinase inhibitors and application thereof
InactiveCN101836991AGood curative effectGood synergyAntineoplastic agentsHeterocyclic compound active ingredientsSide effectEGFR Tyrosine Kinase Inhibitors
The invention relates to a medicament composition containing sorafenib, hepatocyte growth factor receptor (cMet) inhibitors and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and application thereof in preparing medicaments for treating lung cancer, colon cancer, liver cancer, kidney cancer, stomach cancer, encephaloma, sarcoma, pancreatic cancer, ovarian cancer, breast canceror prostatic cancer. The medicament composition has remarkable synergistic effect, improves the curative effect of the medicament, decreases the administration dosage and reduces the occurrence of side effects.
Owner:DINKUM INT INVESTMENT HONG KONG
Methods and compositions for treating C-MET associated cancers
InactiveCN107106645APeptide/protein ingredientsMetabolism disorderMET Receptor Tyrosine KinaseOncology
Owner:YEASTERN BIOTECH
Monoclonal antibodies against c-Met
ActiveUS9068011B2Peptide/protein ingredientsGenetic material ingredientsMonoclonal antibodyMET Receptor Tyrosine Kinase
Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
Owner:GENMAB AS
Hgf-sf monoclonal antibody combinations
InactiveUS20090155284A1Immunoglobulins against growth factorsAntibody ingredientsFactor iiMonoclonal antibody
The present invention provides a combination of anti-HGF / SF antibodies that specifically bind HGF / SF and inhibits HGF / SF activity. The present invention further provides a combination of anti-HGF / SF antibodies comprising three or more anti-HGF / SF antibodies selected from the group consisting of: antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B10, antibody #5 produced from hybridoma 13B1-E4-E10, antibody #7 produced from hybridoma 15D7-B2, and antibody #10 produced from hybridoma 31D4-C9-D4. The invention also provides a method of treating cancer in a subject comprising administering to the subject a combination of anti-HGF / SF antibodies whereby the antibodies bind to a hepatocyte growth factor, whereby the binding of the antibodies to a hepatocyte growth factor results in an inhibition of hepatocyte growth factor binding to the hepatocyte growth factor receptor, whereby the inhibition of hepatocyte growth factor binding to receptor causes an inhibition of cancer growth, thereby treating the cancer.
Owner:UNITED STATES OF AMERICA AS REPRESENTED BY THE SEC DHHS
Method for treating rheumatoid arthritis with an antibody that binds to a hepatocyte growth factor receptor
ActiveUS8133867B2Peptide/protein ingredientsAntipyreticBULK ACTIVE INGREDIENTHepatocyte growth factor
A therapeutic agent for rheumatoid arthritis, particularly a therapeutic agent for ameliorating an inflammatory symptom or bone deformity in rheumatoid arthritis, which comprises an antibody that binds to a hepatocyte growth factor receptor as an active ingredient.
Owner:SEIKAGAKU KOGYO CO LTD
Quinoline compound and preparation method thereof, medicament combination containing compound and application of compound
The invention relates to a quinoline compound which is used as a c-Met depressant and is expressed by the general formula (I) below, a pharmaceutically acceptable salt or pharmaceutically acceptable solvate and a preparation method of the compound, a medicament combination containing the compound and application of the compounds in the preparation of medicaments for preventing or treating diseases relevant to abnormal cell proliferation, morphological change and hyperkinesia with respect to hepatocyte growth factor receptors (HGFR) in an organism as well as diseases relevant to angiogenesis or cancerometastasis, especially medicaments for treating or preventing growth and metastasis of tumors.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Medicament composition containing cMet inhibitor, HDAC (Histone Deacetylases) inhibitor and EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor and application thereof
InactiveCN101837129BGood synergyGood curative effectAntineoplastic agentsPharmaceutical active ingredientsEpidermal growth factor receptor tyrosine kinaseSarcoma
Owner:DINKUM INT INVESTMENT HONG KONG
Hepatocyte growth factor receptor splice variants and methods of using same
InactiveUS7758862B2Good effectHigh affinityPeptide/protein ingredientsAntipyreticMET Receptor Tyrosine KinasePolynucleotide
Owner:COMPUGEN
Methods and compositions for treating c-met associated cancers
InactiveUS20170368119A1Peptide/protein ingredientsMetabolism disorderOncologyImmunomodulatory protein
The present invention provides the use of a fungal immunomodulatory protein (FIP) in manufacturing a medicament for inhibiting hepatocyte growth factor receptor (HGFR) activity in a cell, and for treating HGFR-associated cancer.
Owner:YEASTERN BIOTECH
Hepatocyte growth factor receptor key structural domain fusion protein and application thereof
InactiveCN104628867AEasy to buildLow costImmunoglobulins against cell receptors/antigens/surface-determinantsHybrid peptidesAntiendomysial antibodiesHepatocyte
The invention relates to a hepatocyte growth factor receptor key structural domain fusion protein and an application thereof. The fusion protein comprises an epidermal growth factor receptor strong signal peptide, a hepatocyte growth factor receptor key structural domain and a His tag. The fusion protein is used for the preparation of an antibody. The hepatocyte growth factor receptor key structural domain fusion protein is stably expressed by a lentiviral vector in 293T cells in a long-acting manner and can be specifically bound with the hepatocyte growth factor. The fusion protein has an important role in research and development on neutralizing antibody drugs for screening and blocking a C-Met / HGF signal transduction pathway to further inhibit tumor growth.
Owner:SUZHOU RES INST OF TONGJI UNIV
A radioactive c-met targeting affinity small molecule compound and its application
ActiveCN106008339BTarget-specificQuantitatively accurateIsotope introduction to heterocyclic compoundsRadioactive preparation carriersAbnormal tissue growthDisease
The invention especially relates to a radioactive C-MET-targeted affinity micromolecular compound and application thereof, belonging to the field of medical diagnosis and treatment. According to the invention, in-vivo tracking and imaging of diseases like tumors is realized through radiolabeling of a C-MET receptor antagonist. The radioactive C-MET-targeted affinity micromolecular compound can be used for monitoring the characteristics of biochemical changes of a hepatocyte growth factor receptor, visually displays the distribution and quantity of C-MET and is applicable to specific detection of a plurality of cancers including glioma, lung cancer, prostatic cancer, breast cancer, esophagus cancer, stomach cancer, liver cancer, pancreas cancer, ovarian cancer, rectal cancer and cervical cancer. The radioactive C-MET-targeted affinity micromolecular compound also has certain anticancer activity and has wide clinical application prospect.
Owner:上海准视生物科技有限公司
Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
ActiveUS20130171068A1Promote tissue repairPromote organ regenerationUltrasonic/sonic/infrasonic diagnosticsPeptide/protein ingredientsAgonistHepatocyte growth factor
The NK1 fragment of hepatocyte growth factor (HGF) binds to and activates the Met receptor, a transmembrane receptor tyrosine kinase that plays a critical role in embryonic development and organ formation. The instant application discloses NK1 variant polypeptides which act as agonists or antagonists of HGF. Further disclosed are covalently linked NK1 variant polypeptides. Many of the disclosed variant polypeptides possess improved stability characteristics.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Pharmaceutical composition containing hepatocyte growth factor receptor inhibitor and histone deacetylase inhibitor and application thereof
InactiveCN101653608AGood curative effectGood synergyAmide active ingredientsAntineoplastic agentsTreatment effectSide effect
The invention relates to a pharmaceutical composition containing a hepatocyte growth factor receptor (cMet) inhibitor and a histone deacetylase (HDAC) inhibitor, and application of the pharmaceutical composition in the preparation of medicaments for treating intestinal cancer, sarcoma, glioma, liver cancer, lung cancer, stomach cancer, brain tumors, pancreatic cancer, ovarian cancer, mammary cancer or prostate cancer. The pharmaceutical composition has significant synergistic effect, improves the treatment effect of the medicaments, reduces the administration dose and reduces side effects.
Owner:DINKUM INT INVESTMENT HONG KONG
High affinity combined sites of hgfr and method for identifying its antagonist
InactiveCN101619361APeptide/protein ingredientsMicrobiological testing/measurementNucleotideCancer therapy
The invention discloses a use for screening and developing a medicine effectively useful in the pharmacologia by encoding or containing polynucleotide or polypeptide in at least IPT-3 and IPT-4 structure domain outside the receptor cell of the hepatocyte growth factor, and preferably for treating cancer caused by hepatocyte growth factor receptor misadjusting.
Owner:METHERESIS TRANSLATIONAL RES
Fusion protein of active group of hepatocyte growth factor receptor
ActiveCN102276726ALower immune responsePeptide/protein ingredientsAntibody ingredientsImmunoglobulin Fc FragmentsWilms' tumor
The invention discloses a fusion protein of a hepatocyte growth factor receptor active group, and the fusion protein expresses various fusion proteins of single or more hepatocyte growth factor receptor active groups and human immunoglobulin Fc segments in different combinations by utilizing a molecular biology technology. The fusion protein of the hepatocyte growth factor receptor active group can be efficiently and specifically combined with a growth factor, prevents the growth factor from combining with tumor cells, inhibits growth and transfer of the tumor cells, and treats tumor in a target localization way; and due to the diversity of the hepatocyte growth factor receptor active group, the fusion protein with different affinities and pharmacokinetics can be obtained by virtue of the combination of single or more receptor active groups.
Owner:江苏宁录科技股份有限公司
Trifluoro methyl substituted quinoline or quinoxaline compound and preparation method thereof, and pharmaceutical composition containing the compound and purpose thereof
The invention relates to a quinoline or quinoxaline compound shown as a following general formula I, pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, and a preparation method thereof. The invention further relates to pharmaceutical composition containing the compound and / or pharmaceutically acceptable salt and / or pharmaceutically acceptable solvate thereof, and application of the pharmaceutical composition containing the compound and / or pharmaceutically acceptable salt and / or pharmaceutically acceptable solvate thereof to preparation of medicaments for preventing or treating diseases related to abnormal propagation, morphology and of cells and hyperkinesia that are related to hepatocyte growth factor receptor (HGFR) in organism, and diseases related to angiogenesis or cancerometastasis, and especially medicaments for preventing or treating tumour growth and cancerometastasis.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com